













Identification	
<b>Name</b>	<b>Infliximab</b>
<b>Accession Number</b>	<b>DB00065</b> (BTD00004, BIOD00004)
<b>Type</b>	Biotech
<b>Groups</b>	Approved
<b>Description</b>	Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion.
<b>Protein structure</b>	 ( <a href="https://s3-us-west-2.amazonaws.com/drugbank/protein_structures/full/DB00065.png?1266600394">//s3-us-west-2.amazonaws.com/drugbank/protein_structures/full/DB00065.png?1266600394</a> )
<b>Related Articles</b>	
<b>Protein chemical formula</b>	$C_{6428}H_{9912}N_{1694}O_{1987}S_{46}$
<b>Protein average weight</b>	144190.3 Da
<b>Sequences</b>	Not Available
<b>Synonyms</b>	Not Available

<b>External IDs</b> ⓘ	ABP 710 / BOW015 / CT-P-13 / CT-P13 / TA-650										
<b>Product</b>	Not Available										
<b>Ingredients</b> ⓘ											
<b>Approved Prescription Products</b>	Show <input type="text" value="10"/> entries <input type="text" value="Search"/>										
	<b>Name</b> ↑↓	<b>Dosage</b> ↑↓	<b>Strength</b> ↑↓	<b>Route</b> ↑↓	<b>Labeller</b> ↑↓	<b>Marketing Start</b> ↑↓	<b>Marketing End</b> ↑↓	↑↓	↑↓	↑↓	
	Flixabi	Injection, powder, for solution	100 mg	Intravenous	Samsung Bioepis Uk Limited (Sbuk)	2016-05-26	Not applicable				
	Flixabi	Injection, powder, for solution	100 mg	Intravenous	Samsung Bioepis Uk Limited (Sbuk)	2016-05-26	Not applicable				
	Flixabi	Injection, powder, for solution	100 mg	Intravenous	Samsung Bioepis Uk Limited (Sbuk)	2016-05-26	Not applicable				
	Flixabi	Injection, powder, for solution	100 mg	Intravenous	Samsung Bioepis Uk Limited (Sbuk)	2016-05-26	Not applicable				
	Flixabi	Injection, powder, for solution	100 mg	Intravenous	Samsung Bioepis Uk Limited (Sbuk)	2016-05-26	Not applicable				
	Inflectra	Injection, powder, for solution	100 mg	Intravenous	Hospira, Inc.	2013-09-10	Not applicable				
	Inflectra	Injection, powder, for solution	100 mg	Intravenous	Hospira, Inc.	2013-09-10	Not applicable				
	Inflectra	Injection, powder, for solution	100 mg	Intravenous	Hospira, Inc.	2013-09-10	Not applicable				
	Inflectra	Powder, for solution	100 mg	Intravenous	Celltrion	2014-09-04	Not applicable				
	Inflectra	Injection, powder, for solution	100 mg	Intravenous	Hospira, Inc.	2013-09-10	Not applicable				
Showing 1 to 10 of 20 entries										<input type="button" value="Previous"/> <input type="button" value="1"/> <input type="button" value="2"/> <input type="button" value="Next"/>	
<b>Approved Generic Prescription Products</b>	Not Available										
<b>Approved Over the Counter Products</b>	Not Available										
<b>Unapproved/Other Products</b> ⓘ	Not Available										
<b>International Brands</b>	Not Available										
<b>Brand mixtures</b>	Not Available										

<b>Categories</b>	<ul style="list-style-type: none"> <li>• Amino Acids, Peptides, and Proteins (/categories/DBCAT000021)</li> <li>• Antibodies (/categories/DBCAT000016)</li> </ul>
	<ul style="list-style-type: none"> <li>• Antibodies, Monoclonal (/categories/DBCAT000015)</li> <li>• Antineoplastic and Immunomodulating Agents (/categories/DBCAT002086)</li> <li>• Antirheumatic Agents (/categories/DBCAT000045)</li> <li>• Biologics for Rheumatoid Arthritis Treatment (/categories/DBCAT003020)</li> <li>• Blood Proteins (/categories/DBCAT000019)</li> <li>• Dermatologic Agents (/categories/DBCAT000164)</li> <li>• Gastrointestinal Agents (/categories/DBCAT000048)</li> <li>• Globulins (/categories/DBCAT000022)</li> <li>• Immunoglobulins (/categories/DBCAT000017)</li> <li>• Immunoproteins (/categories/DBCAT000023)</li> <li>• Immunosuppressive Agents (/categories/DBCAT000047)</li> <li>• Proteins (/categories/DBCAT000020)</li> <li>• Serum Globulins (/categories/DBCAT000018)</li> <li>• Tumor Necrosis Factor Alpha (TNF-<math>\alpha</math>) Inhibitors (/categories/DBCAT002087)</li> </ul>
<b>UNII</b>	B72HH48FLU  ( <a href="http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=B72HH48FLU">http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=B72HH48FLU</a> )
<b>CAS number</b>	170277-31-3
Pharmacology	
<b>Indication</b>	To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.
<b>Structured Indications</b> 	<ul style="list-style-type: none"> <li>• Ankylosing Spondylitis (AS) (/indications/DBCOND0046486)</li> <li>• Crohn's Disease (CD) (/indications/DBCOND0052193)</li> <li>• Plaque Psoriasis (/indications/DBCOND0069923)</li> <li>• Psoriatic Arthritis (/indications/DBCOND0068650)</li> <li>• Rheumatoid Arthritis (/indications/DBCOND0027961)</li> <li>• Ulcerative Colitis (UC) (/indications/DBCOND0052192)</li> </ul>
<b>Pharmacodynamics</b>	Infliximab is a chimeric human-murine anti-human tumor necrosis factor (TNF) monoclonal antibody. It binds to tumor necrosis factor alpha (TNF $\alpha$ ) and inhibits binding of TNF $\alpha$ with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.

Mechanism of action															
<p>Infliximab neutralizes the biological activity of TNF<math>\alpha</math> by binding with high affinity to the soluble and transmembrane forms of TNF<math>\alpha</math> and inhibits binding of TNF<math>\alpha</math> with its receptors. Infliximab does not neutralize TNF<math>\beta</math> (lymphotoxin <math>\alpha</math>), a related cytokine that utilizes the same receptors as TNF<math>\alpha</math>. TNF<math>\alpha</math> activation normally induces the release of proinflammatory cytokines, the enhancement of leukocyte migration and activation of neutrophils among others. Neutralization of the biological activity of TNF<math>\alpha</math> leads to an overall reduction in inflammation.</p>															
<table border="1"> <thead> <tr> <th>Target</th> <th>Kind</th> <th>Pharmacological action</th> <th>Actions</th> <th>Organism</th> <th>UniProt ID</th> <th></th> </tr> </thead> <tbody> <tr> <td>Tumor necrosis factor</td> <td>Protein</td> <td><input checked="" type="checkbox"/></td> <td><input checked="" type="checkbox"/> inhibitor</td> <td>Human</td> <td>P01375 <a href="http://www.uniprot.org/uniprot/P01375">Ⓞ</a> (http://www.uniprot.org/uniprot/P01375)</td> <td><input type="button" value="details"/></td> </tr> </tbody> </table>		Target	Kind	Pharmacological action	Actions	Organism	UniProt ID		Tumor necrosis factor	Protein	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> inhibitor	Human	P01375 <a href="http://www.uniprot.org/uniprot/P01375">Ⓞ</a> (http://www.uniprot.org/uniprot/P01375)	<input type="button" value="details"/>
Target	Kind	Pharmacological action	Actions	Organism	UniProt ID										
Tumor necrosis factor	Protein	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> inhibitor	Human	P01375 <a href="http://www.uniprot.org/uniprot/P01375">Ⓞ</a> (http://www.uniprot.org/uniprot/P01375)	<input type="button" value="details"/>									
Related Articles															
<b>Absorption</b>	Onset of action occurs in about 2 weeks in Crohn's disease.														
<b>Volume of distribution</b>	3-6 L														
<b>Protein binding</b>	Not Available														
<b>Metabolism</b>	Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production. Not metabolized by the CYP enzymes.														
<b>Route of elimination</b>	Not Available														
<b>Half life</b>	9.5 days (7-12 days) in patients with Crohn's disease, plaque psoriasis and rheumatoid arthritis														
<b>Clearance</b>	Not Available														
<b>Toxicity</b>	Not Available														
<b>Affected organisms</b>	<ul style="list-style-type: none"> <li>Humans and other mammals</li> </ul>														
<b>Pathways</b>	Not Available														

Pharmacogenomic Effects/ADRs ⓘ	Show <input type="text" value="10"/> entries				Search		
	Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
	Low affinity immunoglobulin gamma Fc region receptor III-A	---	(C;C)	CC Allele (homozygous) <a href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1801274">Ⓞ (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1801274)</a>	Effect Directly Studied	Patients with this genotype have increased ACR20 response when using infliximab to treat rheumatoid arthritis.	<a href="#">Details (/snp_actions/DBSNPE000152)</a>

Showing 1 to 1 of 1 entries

Previous  Next

## Interactions

## Drug Interactions ⓘ

Show <input type="text" value="10"/> entries		Search	
Drug	Interaction	Drug group	
Abatacept (/drugs/DB01281)	The risk or severity of adverse effects can be increased when Infliximab is combined with Abatacept.	Approved	
Adalimumab (/drugs/DB00051)	Adalimumab may increase the immunosuppressive activities of Infliximab.	Approved	
Anakinra (/drugs/DB00026)	The risk or severity of adverse effects can be increased when Infliximab is combined with Anakinra.	Approved	
BCG vaccine (/drugs/DB12768)	The therapeutic efficacy of Bcg can be decreased when used in combination with Infliximab.	Investigational	
Belimumab (/drugs/DB08879)	The risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.	Approved	
Canakinumab (/drugs/DB06168)	The risk or severity of adverse effects can be increased when Infliximab is combined with Canakinumab.	Approved, Investigational	
Certolizumab pegol (/drugs/DB08904)	Infliximab may increase the immunosuppressive activities of Certolizumab pegol.	Approved	
Denosumab (/drugs/DB06643)	The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.	Approved	
Etanercept (/drugs/DB00005)	Etanercept may increase the immunosuppressive activities of Infliximab.	Approved, Investigational	
Fingolimod (/drugs/DB08868)	Infliximab may increase the immunosuppressive activities of Fingolimod.	Approved, Investigational	

Showing 1 to 10 of 33 entries

Previous     Next

<b>Food Interactions</b>	Not Available																	
References																		
<b>Synthesis Reference</b>	Not Available																	
<b>General References</b>	<ol style="list-style-type: none"> <li>1. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallan B, Moore MA, Vilcek J, Daddona P, et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. <i>Mol Immunol.</i> 1993 Nov;30(16):1443-53. [PubMed:8232330] (<a href="http://www.ncbi.nlm.nih.gov/pubmed/8232330">http://www.ncbi.nlm.nih.gov/pubmed/8232330</a>)</li> <li>2. Dubinsky MC, Fleshner PP: Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes. <i>Curr Treat Options Gastroenterol.</i> 2003 Jun;6(3):183-200. [PubMed:12744819] (<a href="http://www.ncbi.nlm.nih.gov/pubmed/12744819">http://www.ncbi.nlm.nih.gov/pubmed/12744819</a>)</li> <li>3. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezaand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. <i>N Engl J Med.</i> 1999 May 6;340(18):1398-405. [PubMed:10228190] (<a href="http://www.ncbi.nlm.nih.gov/pubmed/10228190">http://www.ncbi.nlm.nih.gov/pubmed/10228190</a>)</li> <li>4. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. <i>N Engl J Med.</i> 2004 Feb 26;350(9):876-85. [PubMed:14985485] (<a href="http://www.ncbi.nlm.nih.gov/pubmed/14985485">http://www.ncbi.nlm.nih.gov/pubmed/14985485</a>)</li> <li>5. Hanauer SB: Crohn's disease: step up or top down therapy. <i>Best Pract Res Clin Gastroenterol.</i> 2003 Feb;17(1):131-7. [PubMed:12617888] (<a href="http://www.ncbi.nlm.nih.gov/pubmed/12617888">http://www.ncbi.nlm.nih.gov/pubmed/12617888</a>)</li> <li>6. Link [Link (<a href="http://web.b.ebscohost.com/dynamed/detail?vid=15&amp;sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&amp;hid=110&amp;bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BIPXNpdGU%3d#db=dme&amp;AN=232803&amp;anchor=Mechanism-of-Action-Pharmacokinetics">http://web.b.ebscohost.com/dynamed/detail?vid=15&amp;sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&amp;hid=110&amp;bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BIPXNpdGU%3d#db=dme&amp;AN=232803&amp;anchor=Mechanism-of-Action-Pharmacokinetics</a>)]</li> <li>7. Link [Link (<a href="http://www.google.co.in/patents/US8524217">http://www.google.co.in/patents/US8524217</a>)]</li> </ol>																	
<b>External Links</b>	<table border="1"> <thead> <tr> <th>Resource</th> <th>Link</th> </tr> </thead> <tbody> <tr> <td>UniProt</td> <td>P01857 (<a href="http://www.uniprot.org/uniprot/P01857">http://www.uniprot.org/uniprot/P01857</a>)</td> </tr> <tr> <td>Genbank</td> <td>J00228 (<a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J00228">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J00228</a>)</td> </tr> <tr> <td>PharmGKB</td> <td>PA452639 (<a href="http://www.pharmgkb.org/drug/PA452639">http://www.pharmgkb.org/drug/PA452639</a>)</td> </tr> <tr> <td>Drug Product Database</td> <td>12094 (<a href="http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=12094&amp;lang=eng">http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=12094&amp;lang=eng</a>)</td> </tr> <tr> <td>RxList</td> <td><a href="http://www.rxlist.com/cgi/generic3/infliximab.htm">http://www.rxlist.com/cgi/generic3/infliximab.htm</a> (<a href="http://www.rxlist.com/cgi/generic3/infliximab.htm">http://www.rxlist.com/cgi/generic3/infliximab.htm</a>)</td> </tr> <tr> <td>Drugs.com</td> <td><a href="http://www.drugs.com/cdi/infliximab.html">http://www.drugs.com/cdi/infliximab.html</a> (<a href="http://www.drugs.com/cdi/infliximab.html">http://www.drugs.com/cdi/infliximab.html</a>)</td> </tr> <tr> <td>Wikipedia</td> <td>Infliximab (<a href="http://en.wikipedia.org/wiki/Infliximab">http://en.wikipedia.org/wiki/Infliximab</a>)</td> </tr> </tbody> </table>	Resource	Link	UniProt	P01857 ( <a href="http://www.uniprot.org/uniprot/P01857">http://www.uniprot.org/uniprot/P01857</a> )	Genbank	J00228 ( <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J00228">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J00228</a> )	PharmGKB	PA452639 ( <a href="http://www.pharmgkb.org/drug/PA452639">http://www.pharmgkb.org/drug/PA452639</a> )	Drug Product Database	12094 ( <a href="http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=12094&amp;lang=eng">http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=12094&amp;lang=eng</a> )	RxList	<a href="http://www.rxlist.com/cgi/generic3/infliximab.htm">http://www.rxlist.com/cgi/generic3/infliximab.htm</a> ( <a href="http://www.rxlist.com/cgi/generic3/infliximab.htm">http://www.rxlist.com/cgi/generic3/infliximab.htm</a> )	Drugs.com	<a href="http://www.drugs.com/cdi/infliximab.html">http://www.drugs.com/cdi/infliximab.html</a> ( <a href="http://www.drugs.com/cdi/infliximab.html">http://www.drugs.com/cdi/infliximab.html</a> )	Wikipedia	Infliximab ( <a href="http://en.wikipedia.org/wiki/Infliximab">http://en.wikipedia.org/wiki/Infliximab</a> )	
Resource	Link																	
UniProt	P01857 ( <a href="http://www.uniprot.org/uniprot/P01857">http://www.uniprot.org/uniprot/P01857</a> )																	
Genbank	J00228 ( <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J00228">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J00228</a> )																	
PharmGKB	PA452639 ( <a href="http://www.pharmgkb.org/drug/PA452639">http://www.pharmgkb.org/drug/PA452639</a> )																	
Drug Product Database	12094 ( <a href="http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=12094&amp;lang=eng">http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=12094&amp;lang=eng</a> )																	
RxList	<a href="http://www.rxlist.com/cgi/generic3/infliximab.htm">http://www.rxlist.com/cgi/generic3/infliximab.htm</a> ( <a href="http://www.rxlist.com/cgi/generic3/infliximab.htm">http://www.rxlist.com/cgi/generic3/infliximab.htm</a> )																	
Drugs.com	<a href="http://www.drugs.com/cdi/infliximab.html">http://www.drugs.com/cdi/infliximab.html</a> ( <a href="http://www.drugs.com/cdi/infliximab.html">http://www.drugs.com/cdi/infliximab.html</a> )																	
Wikipedia	Infliximab ( <a href="http://en.wikipedia.org/wiki/Infliximab">http://en.wikipedia.org/wiki/Infliximab</a> )																	
<b>ATC Codes</b>	L04AB02 – Infliximab (/atc/L04AB02) L04AB – Tumor necrosis factor alpha (TNF- $\alpha$ ) inhibitors (/atc/L04AB) L04A – IMMUNOSUPPRESSANTS (/atc/L04A) L04 – IMMUNOSUPPRESSANTS (/atc/L04) L – ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS (/atc/L)																	
<b>AHFS Codes</b>	<ul style="list-style-type: none"> <li>• 92:00.00</li> </ul>																	
<b>PDB Entries</b>	<ul style="list-style-type: none"> <li>• 1IGT (<a href="http://www.rcsb.org/pdb/explore.do?structureId=1IGT">http://www.rcsb.org/pdb/explore.do?structureId=1IGT</a>)</li> </ul>																	
<b>FDA label</b>	Download ( <a href="https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00065.pdf?1265922797">https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00065.pdf?1265922797</a> ) (1.21 MB)																	

**MSDS** Not Available

Clinical Trials

**Clinical Trials** ⓘ

Show  entries

Search

Phase ↑↓	Status ↑↓	Purpose ↑↓	Conditions ↑↓	Count ↑↓
1	Active Not Recruiting	Treatment	Crohn's Disease (CD) (/indications/DBCOND0052193) / Ulcerative Colitis (UC) (/indications/DBCOND0052192)	1 (/drugs/DB00065/clinical_trials?conditions=DBCOND0052193%2CDBCOND0052192&phase=1&purpose=treatment&status=active_not_recruiting)
1	Completed	Basic Science	Healthy Volunteers (/indications/DBCOND0066957)	2 (/drugs/DB00065/clinical_trials?conditions=DBCOND0066957&phase=1&purpose=basic_science&status=completed)
1	Completed	Basic Science	Inflammatory Bowel Diseases (IBD) (/indications/DBCOND0069946) / Ulcerative Colitis (UC) (/indications/DBCOND0052192)	1 (/drugs/DB00065/clinical_trials?conditions=DBCOND0069946%2CDBCOND0052192&phase=1&purpose=basic_science&status=completed)
1	Completed	Prevention	Reperfusion Injury (/indications/DBCOND0032061)	1 (/drugs/DB00065/clinical_trials?conditions=DBCOND0032061&phase=1&purpose=prevention&status=completed)
1	Completed	Treatment	Ankylosing Spondylitis (AS) (/indications/DBCOND0046486)	3 (/drugs/DB00065/clinical_trials?conditions=DBCOND0046486&phase=1&purpose=treatment&status=completed)
1	Completed	Treatment	Graft Versus Host Disease (GVHD) (/indications/DBCOND0051557)	1 (/drugs/DB00065/clinical_trials?conditions=DBCOND0051557&phase=1&purpose=treatment&status=completed)
1	Completed	Treatment	Mucocutaneous Lymph Node Syndrome (/indications/DBCOND0000706)	1 (/drugs/DB00065/clinical_trials?conditions=DBCOND0000706&phase=1&purpose=treatment&status=completed)
1	Completed	Treatment	Rheumatoid Arthritis (/indications/DBCOND0027961)	1 (/drugs/DB00065/clinical_trials?conditions=DBCOND0027961&phase=1&purpose=treatment&status=completed)
1	Completed	Treatment	Scleritis (/indications/DBCOND0001176)	1 (/drugs/DB00065/clinical_trials?conditions=DBCOND0001176&phase=1&purpose=treatment&status=completed)
1	Recruiting	Treatment	Depressive State (/indications/DBCOND0052233)	1 (/drugs/DB00065/clinical_trials?conditions=DBCOND0052233&phase=1&purpose=treatment&status=recruiting)

Showing 1 to 10 of 184 entries

Previous      ...  Next

Pharmacoeconomics

**Manufacturers**

- J&J and Mitsubisi Tanabe

**Packagers**

- Centocor Ortho Biotech Inc. (<http://www.centocororthobiotech.com>)
- Hospira Inc. (<http://www.hospira.com>)

**Dosage forms** Show  entries Search

Form	Route	Strength
Injection, powder, for solution	Intravenous	100 mg
Injection, powder, lyophilized, for solution	Intravenous	100 mg/10mL
Powder, for solution	Intravenous	100 mg
Injection, powder, lyophilized, for solution	Intravenous	100 mg/1

Showing 1 to 4 of 4 entries Previous  Next

**Prices** Show  entries Search

Unit description	Cost	Unit
Remicade 100 mg Solution Vial	821.02USD	vial
Remicade 100 mg vial	789.44USD	vial

Showing 1 to 2 of 2 entries Previous  Next

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

**Patents** Show  entries Search

Patent Number	Pediatric Extension	Approved	Expires (estimated)	
CA2106299  ( <a href="https://patents.google.com/patent/CA2106299">https://patents.google.com/patent/CA2106299</a> )	No	2001-02-06	2012-03-18	

Showing 1 to 1 of 1 entries Previous  Next

**Properties**

State	Property	Value	Source
Liquid	melting point (°C)	61 °C (FAB fragment), 71 °C (whole mAb)	Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
	hydrophobicity	-0.441	Not Available
	isoelectric point	8.25	Not Available



Taxonomy	
<b>Description</b>	Not Available
<b>Kingdom</b>	Organic Compounds
<b>Super Class</b>	Organic Acids
<b>Class</b>	Carboxylic Acids and Derivatives
<b>Sub Class</b>	Amino Acids, Peptides, and Analogues
<b>Direct Parent</b>	Peptides
<b>Alternative Parents</b>	Not Available
<b>Substituents</b>	Not Available
<b>Molecular Framework</b>	Not Available
<b>External Descriptors</b>	Not Available

## Targets

### 1. Tumor necrosis factor (/biodb/polypeptides/P01375)

[Details \(/biodb/polypeptides/P01375\)](/biodb/polypeptides/P01375)

**Kind** Protein  
**Organism** Human  
**Pharmacological action**  yes  
**Actions** inhibitor

**General Function:** Tumor necrosis factor receptor binding

**Specific Function:** Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...

**Gene Name:** TNF

**Uniprot ID:** P01375 [Ⓞ \(http://www.uniprot.org/uniprot/P01375\)](http://www.uniprot.org/uniprot/P01375)

**Uniprot Name:** Tumor necrosis factor

**Molecular Weight:** 25644.15 Da

#### References

1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 [↗](http://www.ncbi.nlm.nih.gov/pubmed/11752352) (http://www.ncbi.nlm.nih.gov/pubmed/11752352)]
2. Mimura T: [Selection of one of the TNF blockers; infliximab and etanercept]. Nihon Rinsho. 2007 Jul;65(7):1282-6. [PubMed:17642244 [↗](http://www.ncbi.nlm.nih.gov/pubmed/17642244) (http://www.ncbi.nlm.nih.gov/pubmed/17642244)]
3. Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51. [PubMed:16052578 [↗](http://www.ncbi.nlm.nih.gov/pubmed/16052578) (http://www.ncbi.nlm.nih.gov/pubmed/16052578)]
4. Danese S, Sans M, Scaldaferrri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006 Feb 15;176(4):2617-24. [PubMed:16456024 [↗](http://www.ncbi.nlm.nih.gov/pubmed/16456024) (http://www.ncbi.nlm.nih.gov/pubmed/16456024)]
5. Magro F, Pereira P, Carneiro F, Veloso FT: Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis? Inflamm Bowel Dis. 2005 Jan;11(1):88-90. [PubMed:15674127 [↗](http://www.ncbi.nlm.nih.gov/pubmed/15674127) (http://www.ncbi.nlm.nih.gov/pubmed/15674127)]
6. Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, Sugimoto M: Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16(1):58-62. [PubMed:16622728 [↗](http://www.ncbi.nlm.nih.gov/pubmed/16622728) (http://www.ncbi.nlm.nih.gov/pubmed/16622728)]
7. Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4 Suppl 2:S22-8. Epub 2002 Mar 27. [PubMed:12110154 [↗](http://www.ncbi.nlm.nih.gov/pubmed/12110154) (http://www.ncbi.nlm.nih.gov/pubmed/12110154)]
8. Sapienza MS, Cohen S, Dimarino AJ: Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004 Sep;49(9):1454-7. [PubMed:15481318 [↗](http://www.ncbi.nlm.nih.gov/pubmed/15481318) (http://www.ncbi.nlm.nih.gov/pubmed/15481318)]
9. Tobin AM, Kirby B: TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57. [PubMed:15691217 [↗](http://www.ncbi.nlm.nih.gov/pubmed/15691217) (http://www.ncbi.nlm.nih.gov/pubmed/15691217)]
10. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8. [PubMed:15691299 [↗](http://www.ncbi.nlm.nih.gov/pubmed/15691299) (http://www.ncbi.nlm.nih.gov/pubmed/15691299)]
11. Popa C, Netea MG, Barrera P, Radstake TR, van Riel PL, Kullberg BJ, Van der Meer JW: Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine. 2005 Apr 21;30(2):72-7. [PubMed:15804598 [↗](http://www.ncbi.nlm.nih.gov/pubmed/15804598) (http://www.ncbi.nlm.nih.gov/pubmed/15804598)]

Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 15:53

#### ABOUT US

About DrugBank  
(/about)  
Wishart Research  
Group  
(http://www.wishartlab.com)

#### SUPPORT

FAQ (/faqs)  
Help  
(/documentation)

#### CONTACT US

DrugBank  
Blog  
(https://blog.drugbankplus.com)  
Email  
Support  
(mailto:support@drugbankplus.com)  
DrugBank  
Plus Support  
(https://www.drugbankplus.com/contact.html?  
ref=drugbank-  
footer)

#### LEGAL

Terms of Use  
(/legal/terms\_of\_use)  
Privacy  
(/legal/privacy\_policy)

#### DRUGBANK PLUS

(HTTPS://WWW.DRUGBANKPLUS.COM)

API Pricing  
(https://www.drugbankplus.com/api.html)  
API Docs  
(https://docs.drugbankplus.com)  
Data Licenses  
(https://www.drugbankplus.com/data.html)

Facebook

[\(https://www.facebook.com/DrugBankDatabase/\)](https://www.facebook.com/DrugBankDatabase/)

Twitter

 [\(https://twitter.com/DrugBankDB\)](https://twitter.com/DrugBankDB)

This project is supported by the Canadian Institutes of Health Research (<http://www.cihr-irsc.gc.ca>) (award #111062), Alberta Innovates - Health Solutions (<http://www.aihealthsolutions.ca>), and by The Metabolomics Innovation Centre (TMIC) (<http://www.metabolomicscentre.ca/>), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta (<http://www.genomealberta.ca>), Genome British Columbia (<http://www.genomebc.ca/>), and Genome Canada (<http://www.genomecanada.ca>), a not-for-profit organization that is leading Canada's national genomics strategy with \$900 million in funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. (<http://omx.io>)

 [\(http://www.cihr-irsc.gc.ca\)](http://www.cihr-irsc.gc.ca) [\(http://www.aihealthsolutions.ca\)](http://www.aihealthsolutions.ca) [\(http://genomealberta.ca\)](http://genomealberta.ca)